Skip to main content

Table 3 Parameter estimates for the final pharmacokinetic model for daily 600 mg EFV

From: CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

Parameter Estimate (% RSE)a bIIV (%RSE)
CL/FTT (L/hr) 7.01 (10) 70.3 (7)
CL/FTC (L/hr) 2.26 (12) 70.3 (7)
C/FLCC (L/hr) 0.539 (24) 70.3 (7)
V/F (L/hr) 150 FIX  
ka (hr −1) 0.18 FIX  
PROP_ERR 0.12  
Effect on CL/F TT , CL/F TC and CL/F CC
CYP2B6GG (%) +93.1 (24%)  
CYP2B6TT (%) −63.4 (9)  
CYP2B6GT (%) 0  
10 kg increase body weight (%) +21.1 (21)  
Females (%) +22.2 (67)  
  1. aRSE, relative standard error (how precise the model is estimating the IIV). bIIV, inter-individual variability reported as percent coefficient of variation. CL/F, oral clearance; CYP2B6*18 TT, extensive metabolizer; TC, Intermediate metabolizer; CC, poor metabolizer; V/F, volume of distribution; ka, first-order absorption rate constant; PROP_ERR, proportional error; CYP2B6 GG, extensive metabolizer; GT, Intermediate metabolizer; TT, poor metabolizer.